Rachelle Perea

BIIB021, an oral, synthetic non-ansamycin Hsp90 inhibitor: Phase I experience

Abir Elfiky, Muhammad Wasif Saif, M. Beeram et al. · Journal of Clinical Oncology · 2008 · 39 citations

Medicine, Oncology, Pharmacology +11

A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer

Giuseppe Curigliano, Geoffrey I. Shapiro, Rebecca Kristeleit et al. · British Journal of Cancer · 2022 · 34 citations · Full text

Medicine, Oncology, Pharmacology +10

Phase 1 study of KT-333, a targeted protein degrader, in patients with relapsed or refractory lymphomas, large granular lymphocytic leukemia, and solid tumors.

Alexander Starodub, Ashwin Gollerkeri, Chris De Savi et al. · Journal of Clinical Oncology · 2022 · 23 citations

Medicine, Cancer Biology, Oncology +12

First-in-human dose-escalation safety and PK trial of a novel intravenous humanized monoclonal CovX body inhibiting angiopoietin 2.

Lee S. Rosen, David S. Mendelson, Richard B. Cohen et al. · Journal of Clinical Oncology · 2010 · 22 citations

Medicine, Oncology, Pharmacology +17

Preliminary Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors

Aditi Shastri, Eric J. Feldman, Alexander Starodub et al. · Blood · 2023 · 18 citations

Pharmacy, Oncology, Pharmacokinetics +16